{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:08:20Z","timestamp":1793394500414,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016036","name":"Health~Holland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016036","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001828","name":"Erasmus University Rotterdam","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013209","name":"Hellenic Foundation for Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013209","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.canlet.2025.217506","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T03:07:54Z","timestamp":1738206474000},"page":"217506","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targets"],"prefix":"10.1016","volume":"614","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5205-097X","authenticated-orcid":false,"given":"Mathijs P.","family":"Scholtes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Akbarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Galaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Alberto","family":"Nakauma-Gonz\u00e1les","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameneh","family":"Bazrafshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9294-5334","authenticated-orcid":false,"given":"Vandana","family":"Solanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8508-6824","authenticated-orcid":false,"given":"Bram","family":"Torenvliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Beikmohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2081-6949","authenticated-orcid":false,"given":"Valeria","family":"Lozovanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahla","family":"Romal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Moulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikoleta","family":"Vavouraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0013-8486","authenticated-orcid":false,"given":"Tsung Wai","family":"Kan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahesh","family":"Algoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6814-0996","authenticated-orcid":false,"given":"Martin E.","family":"van Royen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9319-2205","authenticated-orcid":false,"given":"Andrea","family":"Sacchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry P.P.","family":"van den Bosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Eussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1513-4787","authenticated-orcid":false,"given":"Annelies","family":"de Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert J.L.H.","family":"van Leenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5127-0436","authenticated-orcid":false,"given":"Joost L.","family":"Boormans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantelis","family":"Hatzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert-Jan","family":"Palstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahlita C.M.","family":"Zuiverloon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokameh","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.canlet.2025.217506_bib1","first-page":"209","article-title":"Global cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","article-title":"European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines","volume":"85","author":"Alfred","year":"2024","journal-title":"Eur. Urol."},{"issue":"3","key":"10.1016\/j.canlet.2025.217506_bib3","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2606","volume":"33","author":"Powles","year":"2022","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.canlet.2025.217506_bib4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib5","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1038\/s41467-020-18640-0","article-title":"Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis","volume":"11","author":"Taber","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib6","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1038\/s41467-022-33980-9","article-title":"Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer","volume":"13","author":"Damrauer","year":"2022","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.canlet.2025.217506_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.eururo.2022.01.026","article-title":"Comprehensive molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinoma","volume":"81","author":"Nakauma-Gonz\u00e1lez","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.canlet.2025.217506_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100814","article-title":"Therapeutic significance of ARID1A mutation in bladder cancer","volume":"31","author":"Conde","year":"2022","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.canlet.2025.217506_bib9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2023.03.021","article-title":"Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression","volume":"41","author":"Jana","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib10","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1038\/s41467-019-12037-4","article-title":"ARID1A promotes genomic stability through protecting telomere cohesion","volume":"10","author":"Zhao","year":"2019","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.canlet.2025.217506_bib11","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.canlet.2025.217506_bib12","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1158\/2159-8290.CD-20-1109","article-title":"A CRISPR\/Cas9-Engineered arid1a-deficient human gastric cancer organoid model reveals essential and nonessential modes of oncogenic transformation","volume":"11","author":"Lo","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2025.217506_bib13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3389\/fbioe.2016.00012","article-title":"In vitro tumor models: advantages, disadvantages, variables, and selecting the right platform","volume":"4","author":"Katt","year":"2016","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"9","key":"10.1016\/j.canlet.2025.217506_bib14","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-derived xenograft models: an emerging platform for translational cancer research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41698-021-00168-1","article-title":"Patient-derived organoids as a predictive biomarker for treatment response in cancer patients","volume":"5","author":"Wensink","year":"2021","journal-title":"npj Precis. Oncol."},{"issue":"4","key":"10.1016\/j.canlet.2025.217506_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040874","article-title":"Organoid and spheroid tumor models: techniques and applications","volume":"13","author":"Gunti","year":"2021","journal-title":"Cancers"},{"issue":"7244","key":"10.1016\/j.canlet.2025.217506_bib17","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nature07935","article-title":"Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche","volume":"459","author":"Sato","year":"2009","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib18","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41467-023-37696-2","article-title":"Bladder cancer organoids as a functional system to model different disease stages and therapy response","volume":"14","author":"Minoli","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.canlet.2025.217506_bib19","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.cell.2018.03.017","article-title":"Tumor evolution and drug response in patient-derived organoid models of bladder cancer","volume":"173","author":"Lee","year":"2018","journal-title":"Cell."},{"issue":"10","key":"10.1016\/j.canlet.2025.217506_bib20","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1073\/pnas.1803595116","article-title":"Mouse and human urothelial cancer organoids: a tool for bladder cancer research","volume":"116","author":"Mullenders","year":"2019","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"6","key":"10.1016\/j.canlet.2025.217506_bib21","first-page":"416","article-title":"Patient derived models of bladder cancer enrich the signal of the tumor cell transcriptome facilitating the analysis of the tumor cell compartment","volume":"9","author":"Mastri","year":"2021","journal-title":"Am J Clin Exp Urol"},{"issue":"16","key":"10.1016\/j.canlet.2025.217506_bib22","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib23","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13073-021-00841-x","article-title":"ClinSV: clinical grade structural and copy number variant detection from whole genome sequencing data","volume":"13","author":"Minoche","year":"2021","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib24","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1038\/s41467-019-12037-4","article-title":"ARID1A promotes genomic stability through protecting telomere cohesion","volume":"10","author":"Zhao","year":"2019","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.canlet.2025.217506_bib25","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1158\/1078-0432.CCR-05-1045","article-title":"A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine","volume":"11","author":"van Oers","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1756-0500-2-66","article-title":"A SNaPshot assay for the rapid and simple detection of four common hotspot codon mutations in the PIK3CA gene","volume":"2","author":"Hurst","year":"2009","journal-title":"BMC Res. Notes"},{"issue":"2","key":"10.1016\/j.canlet.2025.217506_bib27","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","article-title":"Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome","volume":"65","author":"Allory","year":"2014","journal-title":"Eur. Urol."},{"issue":"5","key":"10.1016\/j.canlet.2025.217506_bib28","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.canlet.2025.217506_bib29","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2023.03.021","article-title":"Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression","volume":"41","author":"Jana","year":"2023","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrm714","article-title":"Sibling rivalry in the E2F family","volume":"3","author":"Trimarchi","year":"2002","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"8","key":"10.1016\/j.canlet.2025.217506_bib31","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.dnarep.2004.03.034","article-title":"The emerging role of E2F-1 in the DNA damage response and checkpoint control","volume":"3","author":"Stevens","year":"2004","journal-title":"DNA Repair"},{"issue":"7","key":"10.1016\/j.canlet.2025.217506_bib32","first-page":"739","article-title":"Distinct and overlapping roles for E2F family members in transcription, proliferation and apoptosis","volume":"6","author":"DeGregori","year":"2006","journal-title":"Curr. Mol. Med."},{"issue":"3","key":"10.1016\/j.canlet.2025.217506_bib33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.tcb.2009.01.002","article-title":"Atypical E2Fs: new players in the E2F transcription factor family","volume":"19","author":"Lammens","year":"2009","journal-title":"Trends Cell Biol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib34","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10050","article-title":"Structural insights into the DNA-binding specificity of E2F family transcription factors","volume":"6","author":"Morgunova","year":"2015","journal-title":"Nat. Commun."},{"issue":"D1","key":"10.1016\/j.canlet.2025.217506_bib35","doi-asserted-by":"crossref","first-page":"D882","DOI":"10.1093\/nar\/gkz1062","article-title":"New developments on the Encyclopedia of DNA Elements (ENCODE) data portal","volume":"48","author":"Luo","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"9","key":"10.1016\/j.canlet.2025.217506_bib72","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1158\/0008-5472.CAN-13-3608","article-title":"SWI\/SNF factors required for cellular resistance to DNA damage include ARID1A and ARID1B and show interdependent protein stability","volume":"74","author":"Watanabe","year":"2014","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.canlet.2025.217506_bib36","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1101\/gr.080622.108","article-title":"E2F in vivo binding specificity: comparison of consensus versus nonconsensus binding sites","volume":"18","author":"Rabinovich","year":"2008","journal-title":"Genome Res."},{"issue":"4","key":"10.1016\/j.canlet.2025.217506_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.xgen.2024.100528","article-title":"Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature","volume":"4","author":"Nakauma-Gonz\u00e1lez","year":"2024","journal-title":"Cell Genomics"},{"issue":"12","key":"10.1016\/j.canlet.2025.217506_bib38","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrm3474","article-title":"The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis","volume":"13","author":"Carmena","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"5","key":"10.1016\/j.canlet.2025.217506_bib39","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1535-6108(03)00110-7","article-title":"Chk1 and Chk2 kinases in checkpoint control and cancer","volume":"3","author":"Bartek","year":"2003","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.canlet.2025.217506_bib40","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s00280-020-04112-1","article-title":"Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer","volume":"86","author":"Shimizu","year":"2020","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"4","key":"10.1016\/j.canlet.2025.217506_bib41","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/annonc\/mdr353","article-title":"A phase II study of YM155, a novel small-molecule suppressor of survivin, in castration-resistant taxane-pretreated prostate cancer","volume":"23","author":"Tolcher","year":"2012","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.canlet.2025.217506_bib42","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.3109\/10428194.2015.1113275","article-title":"A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma","volume":"57","author":"Papadopoulos","year":"2016","journal-title":"Leuk. Lymphoma"},{"issue":"17","key":"10.1016\/j.canlet.2025.217506_bib43","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1158\/0008-5472.CAN-07-1343","article-title":"YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts","volume":"67","author":"Nakahara","year":"2007","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.canlet.2025.217506_bib45","doi-asserted-by":"crossref","first-page":"776","DOI":"10.7150\/jca.41296","article-title":"Pan-cancer analysis of ARID1A alterations as biomarkers for immunotherapy outcomes","volume":"11","author":"Jiang","year":"2020","journal-title":"J. Cancer"},{"issue":"7517","key":"10.1016\/j.canlet.2025.217506_bib46","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","article-title":"Comprehensive molecular characterization of gastric adenocarcinoma","volume":"513","author":"Bass","year":"2014","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.canlet.2025.217506_bib47","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ccell.2018.12.009","article-title":"Targeting the vulnerability of glutathione metabolism in arid1a-deficient cancers","volume":"35","author":"Ogiwara","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.canlet.2025.217506_bib48","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nm.3799","article-title":"Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers","volume":"21","author":"Bitler","year":"2015","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.canlet.2025.217506_bib49","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/nm.3968","article-title":"SWI\/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2","volume":"21","author":"Kim","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.canlet.2025.217506_bib50","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pharmthera.2018.05.001","article-title":"ARID1A loss in cancer: towards a mechanistic understanding","volume":"190","author":"Mathur","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.canlet.2025.217506_bib51","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2023.03.021","article-title":"Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression","volume":"41","author":"Jana","year":"2023","journal-title":"Cancer Cell"},{"issue":"6512","key":"10.1016\/j.canlet.2025.217506_bib52","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1126\/science.aba8347","article-title":"Extensive heterogeneity in somatic mutation and selection in the human bladder","volume":"370","author":"Lawson","year":"2020","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.canlet.2025.217506_bib53","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s43018-020-0102-y","article-title":"Applications of organoids for cancer biology and precision medicine","volume":"1","author":"Lo","year":"2020","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib54","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41467-023-37696-2","article-title":"Bladder cancer organoids as a functional system to model different disease stages and therapy response","volume":"14","author":"Minoli","year":"2023","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib55","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41698-023-00466-w","article-title":"Patient-derived organoids identify tailored therapeutic options and determinants of plasticity in sarcomatoid urothelial bladder cancer","volume":"7","author":"Garioni","year":"2023","journal-title":"npj Precis. Oncol."},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib56","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1038\/s41467-019-12307-1","article-title":"Urothelial organoids originating from Cd49f(high) mouse stem cells display Notch-dependent differentiation capacity","volume":"10","author":"Santos","year":"2019","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.canlet.2025.217506_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107762","article-title":"Patient-derived ovarian cancer organoids mimic clinical response and exhibit heterogeneous inter- and intrapatient drug responses","volume":"31","author":"de Witte","year":"2020","journal-title":"Cell Rep."},{"issue":"6378","key":"10.1016\/j.canlet.2025.217506_bib58","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1126\/science.aao2774","article-title":"Patient-derived organoids model treatment response of metastatic gastrointestinal cancers","volume":"359","author":"Vlachogiannis","year":"2018","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.stem.2019.10.010","article-title":"Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer","volume":"26","author":"Yao","year":"2020","journal-title":"Cell Stem Cell"},{"issue":"3","key":"10.1016\/j.canlet.2025.217506_bib60","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/nm.3802","article-title":"Modeling colorectal cancer using CRISPR-Cas9-mediated engineering of human intestinal organoids","volume":"21","author":"Matano","year":"2015","journal-title":"Nat Med"},{"issue":"7550","key":"10.1016\/j.canlet.2025.217506_bib61","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature14415","article-title":"Sequential cancer mutations in cultured human intestinal stem cells","volume":"521","author":"Drost","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.canlet.2025.217506_bib62","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.cell.2018.07.027","article-title":"Divergent routes toward Wnt and R-spondin niche independency during human gastric carcinogenesis","volume":"174","author":"Nanki","year":"2018","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.canlet.2025.217506_bib63","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/sj.emboj.7601541","article-title":"Distinct mammalian SWI\/SNF chromatin remodeling complexes with opposing roles in cell-cycle control","volume":"26","author":"Nagl","year":"2007","journal-title":"Embo j"},{"issue":"5","key":"10.1016\/j.canlet.2025.217506_bib64","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ccell.2017.10.007","article-title":"Arid1a has context-dependent oncogenic and tumor suppressor functions in liver cancer","volume":"32","author":"Sun","year":"2017","journal-title":"Cancer Cell"},{"issue":"20","key":"10.1016\/j.canlet.2025.217506_bib65","doi-asserted-by":"crossref","first-page":"9236","DOI":"10.1158\/0008-5472.CAN-05-1225","article-title":"The p270 (ARID1A\/SMARCF1) subunit of mammalian SWI\/SNF-related complexes is essential for normal cell cycle arrest","volume":"65","author":"Nagl","year":"2005","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.canlet.2025.217506_bib66","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12876-023-03059-w","article-title":"ARID1A deficiency promotes progression and potentiates therapeutic antitumour immunity in hepatitis B virus-related hepatocellular carcinoma","volume":"24","author":"Xing","year":"2024","journal-title":"BMC Gastroenterol."},{"issue":"Database issue","key":"10.1016\/j.canlet.2025.217506_bib67","doi-asserted-by":"crossref","first-page":"D1140","DOI":"10.1093\/nar\/gku1092","article-title":"Cyclebase 3.0: a multi-organism database on cell-cycle regulation and phenotypes","volume":"43","author":"Santos","year":"2015","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.canlet.2025.217506_bib68","doi-asserted-by":"crossref","first-page":"414","DOI":"10.15252\/embr.201540984","article-title":"Feedback regulation between atypical E2Fs and APC\/CCdh1 coordinates cell cycle progression","volume":"17","author":"Boekhout","year":"2016","journal-title":"EMBO Rep."},{"issue":"5","key":"10.1016\/j.canlet.2025.217506_bib69","doi-asserted-by":"crossref","DOI":"10.15252\/embj.201797877","article-title":"Chk1 and 14-3-3 proteins inhibit atypical E2Fs to prevent a permanent cell cycle arrest","volume":"37","author":"Yuan","year":"2018","journal-title":"Embo j."},{"issue":"3","key":"10.1016\/j.canlet.2025.217506_bib70","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s10689-012-9599-2","article-title":"The risk of gastric cancer in carriers of CHEK2 mutations","volume":"12","author":"Teodorczyk","year":"2013","journal-title":"Fam. Cancer"},{"issue":"20","key":"10.1016\/j.canlet.2025.217506_bib71","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1038\/emboj.2010.218","article-title":"Cooperative functions of Chk1 and Chk2 reduce tumour susceptibility in vivo","volume":"29","author":"Niida","year":"2010","journal-title":"Embo J"},{"issue":"17","key":"10.1016\/j.canlet.2025.217506_bib73","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1038\/sj.emboj.7601291","article-title":"Mammalian SWI\/SNF complexes facilitate DNA double-strand break repair by promoting gamma-H2AX induction","volume":"25","author":"Park","year":"2006","journal-title":"Embo J"},{"key":"10.1016\/j.canlet.2025.217506_bib74","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13837","article-title":"ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A","volume":"7","author":"Williamson","year":"2016","journal-title":"Nat. Commun."},{"issue":"7451","key":"10.1016\/j.canlet.2025.217506_bib75","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature12146","article-title":"BAF complexes facilitate decatenation of DNA by topoisomerase II\u03b1","volume":"497","author":"Dykhuizen","year":"2013","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.canlet.2025.217506_bib76","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ygyno.2022.09.019","article-title":"A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer","volume":"167","author":"Konstantinopoulos","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"21","key":"10.1016\/j.canlet.2025.217506_bib77","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.93.21.11382","article-title":"Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector","volume":"93","author":"Naldini","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.canlet.2025.217506_bib78","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.canlet.2025.217506_bib79","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat. Methods"},{"issue":"3","key":"10.1016\/j.canlet.2025.217506_bib80","doi-asserted-by":"crossref","DOI":"10.1093\/bib\/bbaa156","article-title":"Integrative, normalization-insusceptible statistical analysis of RNA-Seq data, with improved differential expression and unbiased downstream functional analysis","volume":"22","author":"Fanidis","year":"2020","journal-title":"Briefings Bioinf."},{"issue":"12","key":"10.1016\/j.canlet.2025.217506_bib81","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"issue":"2","key":"10.1016\/j.canlet.2025.217506_bib82","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1039\/C5MB00663E","article-title":"ReactomePA: an R\/Bioconductor package for reactome pathway analysis and visualization","volume":"12","author":"Yu","year":"2016","journal-title":"Mol. Biosyst."},{"issue":"9","key":"10.1016\/j.canlet.2025.217506_bib83","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/gb-2008-9-9-r137","article-title":"Model-based analysis of ChIP-seq (MACS)","volume":"9","author":"Zhang","year":"2008","journal-title":"Genome Biol."},{"issue":"7381","key":"10.1016\/j.canlet.2025.217506_bib84","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/nature10730","article-title":"Differential oestrogen receptor binding is associated with clinical outcome in breast cancer","volume":"481","author":"Ross-Innes","year":"2012","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.canlet.2025.217506_bib85","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","article-title":"Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities","volume":"38","author":"Heinz","year":"2010","journal-title":"Mol Cell"},{"issue":"W1","key":"10.1016\/j.canlet.2025.217506_bib86","doi-asserted-by":"crossref","first-page":"W83","DOI":"10.1093\/nar\/gkae410","article-title":"The Galaxy platform for accessible, reproducible, and collaborative data analyses: 2024 update","volume":"52","author":"The Galaxy","year":"2024","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2025.217506_bib87","first-page":"6","article-title":"A package for survival analysis in R","volume":"3","author":"Therneau","year":"2024","journal-title":"R package version"},{"key":"10.1016\/j.canlet.2025.217506_bib88","series-title":"R Foundation for Statistical Computing","article-title":"R: a language and environment for statistical computing","year":"2017"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525000709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383525000709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T22:57:57Z","timestamp":1760741877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383525000709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":87,"alternative-id":["S0304383525000709"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217506","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.07.29.601702","asserted-by":"object"}]},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrative analysis of patient-derived tumoroids and ex vivo organoid modelling of ARID1A loss in bladder cancer reveals therapeutic molecular targets","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2025.217506","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"217506"}}